Table 1.
Characteristics of eligible studies
| Study | Study period | No. of cases | Component of IMPC* | TNM stage | Follow-up time(M) | Survival data a | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IMPC | IDC | OS | DSS | RFS | LRRFS | DMFS | |||||
| Tang [30] | 2017 | 170 | 728 | mixed | I,II,III | median 40 | 94.5% vs 90.6% (P = 0.592) |
– | 82.1% vs 90.6% (P = 0.001) |
86.9% vs 97.1% (P < 0.001) |
91.5% vs 88.3% (P = 0.923) |
| Li [23] | 2016 | 33 | 347 | mixed | I,II,III | median 39 | 97% vs 94.2% (P = 0.78) |
– | 87.9% vs 86.2% (P = 0.88) |
93.9% vs 89.0% (P = 0.88) |
90.9% vs 89.0% (P = 0.97) |
| Yu [21] | 2015 | 267 | 267 | mixed | I,II,III | median 59 | 97.7% vs 95.7% (P = 0.67) |
– | 85.0% vs 92.1% (P = 0.07) |
91.8% vs 96.3% (P = 0.03) |
91.4% vs 93.3% (P = 0.52) |
| Chen [24] | 2015 | 95 | 200 | mixed | I,II,III | median 60 | 81.9% vs 79.8% (P = 0.475) |
– | – | 71.4% vs 89.8% (P < 0.001) |
79.8% vs 73.7% (P = 0.091) |
| Shi [22] | 2014 | 188 | 1289 | mixed | I,II,III | median40.5 | – | 67.1% vs 87.5% (P < 0.001) |
75.9% vs 89.5% (P < 0.001) |
– | – |
| Liu [19] | 2014 | 51 | 102 | mixed | I,II,III | median 51 | – | – | 84.3% vs 78.4% (P = 0.606) |
– | – |
| Chen [20] | 2014 | 636 | 297,735 | unknown | I,II,III,IV | median 48 | 82.9% vs 80.5% (P = 0.086) |
91.8% vs 88.6% (P = 0.086) |
– | – | – |
| Vingiani [25] | 2013 | 49 | 13,487 | pure | I,II,III | median 51 | 89.8% vs 90.8% (P = 0.80) |
– | 75.5% vs 79.6% (P = 0.48) |
– | – |
| Gokce [12] | 2013 | 103 | 34 | mixed | I,II,III | mean 63.5 | – | 75.9% vs 82.4% (P = 0.44) |
– | – | – |
| Kuba [26] | 2011 | 10 | 162 | mixed | I,II,III | median 72 | – | 90% vs 94.4% |
90% vs 89.8% |
– | – |
| Yu [27] | 2010 | 72 | 144 | mixed | I,II,III | median 45 | 86.0%vs 87.7% (P = 0.18) |
– | 68.2% vs 81.4% (P = 0.046) |
84.7% vs 94.4% (P = 0.0024) |
78.1% vs 79.3% (P = 0.87) |
| Kim [28] | 2010 | 61 | 221 | pure | I,II,III | mean 38.6 | – | – | 86.9% vs 94.6% (P = 0.049) |
– | – |
| Chen [17] | 2008 | 100 | 100 | mixed | I,II,III,IV | mean 60.1 | 59% vs 77% (P = 0.004) |
63.3% vs 81% (P = 0.005) |
– | – | – |
| Zekioglu [29] | 2004 | 53 | 60 | mixed | I,II,III | mean 56.5 | – | 72.2% vs 81.7% NS |
– | – | – |
Abbreviations: IMPC, Invasive micropapillary carcinoma; IDC, Invasive ductal carcinoma; OS, Overall survival; DSS, Disease-specific survival; RFS, Relapse-free Survival; LRRFS, Local-regional recurrence free survival; DMFS, Distant metastasis-free survival; NS, Not significant
aAll percentage was for IMPC vs IDC%
*At least 75% of the micropapillary component identified in an IDC to be defined as pure IMPC